BNC210 trial results... not far away

The company said it expected to report trial results from its anti-anxiety compound BNC210 shortly.
“In June 2016 Bionomics announced the completion of dosing in a Phase 2 trial in patients with generalised anxiety disorder which is evaluating the capacity of BNC210 to engage brain systems relevant to anxiety using functional magnetic resonance imaging,’’ the company said.
“The clinical trial has been conducted at The Institute of Psychiatry, Psychology & Neuroscience at King’s College in London and data is anticipated by 30 September 2016.’’

http://www.adelaidenow.com.au/busin...e/news-story/13c75a52e9f82c1d4a800286cc27a261